Immutep Limited

Informe acción NasdaqGM:IMMP

Capitalización de mercado: US$59.2m

Immutep Dirección

Dirección controles de criterios 2/4

El CEO de Immutep es Marc Voigt , nombrado en Nov 2012, tiene una permanencia de 13.5 años. compensación anual total es A$1.17M, compuesta por 46.5% salario y 53.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 1% de las acciones de la empresa, por valor de $593.89K. La antigüedad media del equipo directivo y de la junta directiva es de 8.4 años y 4 años, respectivamente.

Información clave

Marc Voigt

Chief Executive Officer (CEO)

AU$1.2m

Compensación total

Porcentaje del salario del CEO46.51%
Permanencia del CEO13.5yrs
Participación del CEO1.0%
Permanencia media de la dirección8.4yrs
Promedio de permanencia en la Junta Directiva4yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • May 08

Immutep Limited: Surging On Positive Head And Neck Data

Summary Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval. The positive TACTI-003 readout strengthens my "Buy" sentiment, though risks remain in this challenging cancer treatment landscape. Read the full article on Seeking Alpha
Seeking Alpha • Jan 28

Immutep Limited: Continuing To Make The Case For Eftilagimod

Summary Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential. Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials without immediate funding concerns. Recent clinical data suggest meaningful advancements in LAG-3 therapeutics, reinforcing the investment thesis and highlighting IMMP's undervalued status. Read the full article on Seeking Alpha
Seeking Alpha • Nov 15

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Summary Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data from the phase 1 INSIGHT-003 study is expected in 2025, with plans to initiate a phase 3 TACTI-004 study targeting the same patient population. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031. Results from the phase 2b TACTI-003 study, using efti + KEYTRUDA to treat 1st-line recurrent/metastatic head and neck squamous cell carcinoma, expected in 2025; OS set as primary endpoint. Read the full article on Seeking Alpha
Seeking Alpha • Jul 15

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Summary Immutep Limited achieved positive results in the phase 2b study, using efti + Keytruda for the treatment of patients with 1st-line head and neck squamous cell carcinoma; Both PD-L1 positive and negative patients. Company to meet with FDA to be in a position to initiate a phase 3 study using efti + Keytruda for the treatment of patients with 1st-line HNSCC. Merck supply collaboration agreement in place to advance phase 3 study, using efti + Keytruda + chemotherapy for the treatment of 1stline NSCLC patients. Keytruda had become one of the top-selling drugs in 2023, with sales exceeding $25 billion; Efti has shown to help double several efficacy measures when added to Keytruda. Read the full article on Seeking Alpha
Seeking Alpha • May 01

Immutep: Realizing The Expected Catalysts, With More To Come

Summary Immutep Limited is focused on developing novel treatments targeting LAG3, an immune checkpoint, for various tumor types. The company's pipeline includes eftilagimod, which has shown promising response rates in thoracic malignancies. Immutep should have sufficient funding for 9–10 quarters of research and has demonstrated promising early signals of efficacy and safety. Read the full article on Seeking Alpha
Seeking Alpha • Oct 04

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

The U.S. Food and Drug Administration (FDA) granted fast track designation to Immutep's (NASDAQ:IMMP) eftilagimod alpha (IMP321) in combination with Merck's (NYSE:MRK) Keytruda (pembrolizumab) to treat first line non-small cell lung cancer (NSCLC). The combo was granted the status for initial treatment of patients with stage 3B/4 NSCLC expressing PD-L1 Tumor Proportion Score ≥1%, not amenable to EGFR/ALK based therapy, due to data from a phase 2 trial called TACTI-002/KEYNOTE-798, the company said in an Oct. 4 press release. "Efti also offers a chemotherapy-free option for NSCLC patients in need of less toxic and more durable solutions," said Immutep CEO Marc Voigt. The efti/Keytruda combo had previously received the FDA's fast track status in April 2021 as a first-line treatment for recurrent or metastatic Head and Neck Squamous Cell Carcinoma. IMMP +7.21% to $1.71 premarket Oct. 4
Seeking Alpha • Sep 23

Immutep secures €1.8M cash in French government's research tax credit

Immutep (NASDAQ:IMMP) announced Friday it has received €1.8M cash from the French government in research and development tax incentive payment. The incentive comes under the government's research tax credit scheme under which French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure. The biotech firm said it intends to use the proceeds to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761. Stock is up 5% in pre-market trading. Earlier: Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo
Seeking Alpha • Aug 30

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Immutep (NASDAQ:IMMP) said the Japanese Patent Office granted a new patent for eftilagimod alpha in combination with a PD-1 pathway inhibitor. The patent titled, 'Combined Preparations for the Treatment of Cancer or Infection' protects intellectual property related to combined therapeutic preparations consisting of  immunotherapy candidate eftilagimod alpha and an anti-PD-(L)1 antibody, the company said in an Aug. 30 press release. The company added that the claims are also directed to related methods of use in treating cancer and infection. "This is especially meaningful when coupled with the very promising data we have reported from TACTI-002 in three cancer indications, along with the initiation of TACTI-003 in the past 12 months," said Immutep CEO Marc Voigt. The patent is expected to expire Jan. 8, 2036.
Seeking Alpha • Jul 06

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Immutep (NASDAQ:IMMP) said it received a patent from the Japanese Patent Office related to its pre-clinical product candidate IMP761. The patent number number 7074341 titled 'Anti-LAG-3 Antibodies' is related to pharmaceutical compositions comprising IMP761 and the use of the compositions to treat T-cell mediated inflammatory and autoimmune diseases, according to the company's July 6 press release. The patent will expiry on Sept. 1, 2036.
Seeking Alpha • Jun 12

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Immutep has been developing anti-LAG3 compounds for over a decade. Recent approval of the first such compound from BMY was a watershed event. However, IMMP has a long way to go.
Seeking Alpha • Mar 21

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

FDA approval of Bristol Myers Opdualag/relatlimab anti-LAG3 carries positive implications for LAG3 pure-play Immutep’s entire pipeline. From an anti-LAG3 perspective, the FDA approval is directly positive for Immutep's recently unveiled oral, small molecule anti-LAG3 program and its out-licensed anti-LAG3 program to Novartis. Like anti-PD1 (Keytruda, Opvido) & anti-CLTA4 (Yervoy), LAG3 may be a key checkpoint in oncology. Yet, unlike PD1/CTLA4, LAG3 is unique in that both its activation & inhibition kills cancer. This relatively unknown pure-play on the emerging checkpoint LAG3 (Lymphocyte Activating Gene-3) has collaborations with Novartis, Merck, Pfizer, Merck KGaA, GlaxoSmithKline, EOC Pharma, Labcorp, etc. As its clinical data continues to strengthen, like it consistently has over the past few years, Immutep is seemingly well situated for strategic deals or its potential acquisition.
Seeking Alpha • Jun 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Immutep (IMMP) has signed an agreement to commence a new Phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha (“efti” or “IMP321”) in conjunction with an existing approved standard of care therapy consisting of a chemotherapy agent and an anti-PD-1 therapy. INSIGHT-003 will be run as an amendment to the protocol of the ongoing INSIGHT trial as the third arm (Stratum C) with Prof. Dr. Salah-Eddin Al-Batran as lead investigator. Up to 20 patients

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Marc Voigt en comparación con los beneficios de Immutep?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2025n/an/a

-AU$84m

Sep 30 2025n/an/a

-AU$73m

Jun 30 2025AU$1mAU$546k

-AU$61m

Mar 31 2025n/an/a

-AU$53m

Dec 31 2024n/an/a

-AU$44m

Sep 30 2024n/an/a

-AU$43m

Jun 30 2024AU$1mAU$477k

-AU$43m

Mar 31 2024n/an/a

-AU$42m

Dec 31 2023n/an/a

-AU$41m

Sep 30 2023n/an/a

-AU$40m

Jun 30 2023AU$1mAU$440k

-AU$40m

Mar 31 2023n/an/a

-AU$38m

Dec 31 2022n/an/a

-AU$37m

Sep 30 2022n/an/a

-AU$34m

Jun 30 2022AU$943kAU$428k

-AU$32m

Mar 31 2022n/an/a

-AU$29m

Dec 31 2021n/an/a

-AU$26m

Sep 30 2021n/an/a

-AU$28m

Jun 30 2021AU$995kAU$409k

-AU$30m

Mar 31 2021n/an/a

-AU$29m

Dec 31 2020n/an/a

-AU$27m

Sep 30 2020n/an/a

-AU$20m

Jun 30 2020AU$926kAU$411k

-AU$13m

Mar 31 2020n/an/a

-AU$15m

Dec 31 2019n/an/a

-AU$16m

Sep 30 2019n/an/a

-AU$17m

Jun 30 2019AU$837kAU$399k

-AU$18m

Compensación vs. Mercado: La compensación total de Marc($USD842.04K) está por encima de la media de empresas de tamaño similar en el mercado US ($USD626.93K).

Compensación vs. Ingresos: La compensación de Marc ha aumentado mientras la empresa no es rentable.

CEO

Marc Voigt (52 yo)

13.5yrs
Permanencia
AU$1,174,480
Compensación

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Marc Voigt
CEO, MD13.5yrsAU$1.17m1%
$ 593.9k
Deanne Miller
COO, General Counsel & Joint Company Secretary13.6yrsAU$680.39k0.19%
$ 115.1k
Frederic Triebel
Chief Scientific Officer & Executive Director11.4yrsAU$945.88k0.78%
$ 462.7k
Christian Mueller
Chief Development Officer2.6yrsAU$505.98k0.26%
$ 151.5k
Stephan Winckels
Chief Medical Officerless than a yearsin datos0.0063%
$ 3.7k
Indira Naidu
Joint Company Secretary5.3yrssin datossin datos
8.4yrs
Permanencia media
52yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de IMMP es experimentado (8.4 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Marc Voigt
CEO, MD11.8yrsAU$1.17m1%
$ 593.9k
Frederic Triebel
Chief Scientific Officer & Executive Director3.7yrsAU$945.88k0.78%
$ 462.7k
Russell Howard
Independent Non-Executive Chairman13yrsAU$352.00k0.12%
$ 69.0k
Pete Meyers
Independent Non-Executive Deputy Chairman12.3yrsAU$76.48k0.27%
$ 162.7k
Martine Piccart
Chairman of Clinical Advisory Board8.9yrssin datossin datos
Scott Antonia
Member of Clinical Advisory Board4yrssin datossin datos
Leisha Emens
Member of Clinical Advisory Board4yrssin datossin datos
Elisabeth Boyce
Independent Non-Executive Director3.1yrsAU$100.85k0.029%
$ 17.0k
Salah-Eddin Al-Batran
Member of Clinical Advisory Board8.9yrssin datossin datos
Martin Forster
Member of Clinical Advisory Board4yrssin datossin datos
Hans Wildiers
Member of Clinical Advisory Board4yrssin datossin datos
4.0yrs
Permanencia media
62.5yo
Promedio de edad

Junta con experiencia: La junta directiva de IMMP se considera experimentada (4 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/26 03:22
Precio de las acciones al final del día2026/05/26 00:00
Beneficios2025/12/31
Ingresos anuales2025/06/30

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Immutep Limited está cubierta por 14 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Melissa BensonBarrenjoey Markets Pty Limited
Thomas WakimBell Potter
Dylan DupuisB. Riley Securities, Inc.